ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,807Medicare Part D Prescriptions Filled, Including Refills
$523K Total Retail Price of All Prescriptions
450 Patients Receiving at Least One Drug in Part D
96%Patients 65 Years and Older
20% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
LEVOTHYROXINE SODIUM 470 447
AMLODIPINE BESYLATE 316 316
TRAZODONE HCL 298 279
NAMENDA 262 262
LISINOPRIL 237 233
SIMVASTATIN 232 216
DONEPEZIL HCL 225 225
FUROSEMIDE 220 220
METOPROLOL TARTRATE 216 213
HYDROCODONE-ACETAMINOPHEN 202 180 S3
ATORVASTATIN CALCIUM 195 194
MIRTAZAPINE 167 167
HYDROCHLOROTHIAZIDE 166 160
OMEPRAZOLE 164 150
LOSARTAN POTASSIUM 157 157
WARFARIN SODIUM 153 145
POTASSIUM CHLORIDE 145 137
CITALOPRAM HBR 144 144
SERTRALINE HCL 135 135
TRAMADOL HCL 125 112
TAMSULOSIN HCL 92 88
CLOPIDOGREL 91 91
CYMBALTA 91 90
ATENOLOL 89 89
GABAPENTIN 88 86
QUETIAPINE FUMARATE 81 81
CARVEDILOL 79 79
FLUTICASONE PROPIONATE 76 71
EXELON 73 73
LIDODERM 73 70
ALENDRONATE SODIUM 72 72
ESCITALOPRAM OXALATE 66 66
ISOSORBIDE MONONITRATE ER 64 64
NEXIUM 63 63
PRAVASTATIN SODIUM 60 60
METFORMIN HCL 60 59
SYNTHROID 59 59
KLOR-CON 10 56 56
DIGOXIN 56 56
PLAVIX 56 56
PANTOPRAZOLE SODIUM 55 51
METOPROLOL SUCCINATE 53 53
COUMADIN 53 53
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 30, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.